PHMB对Biomphalaria glabrata的新陈代谢和行为影响:控制杆菌病的策略
M E A Almeida1, V C S Amaral2, T L Costa3
1Universidade Estadual de Goiás - UEG, Laboratório de Pesquisa da Interação Parasito-Hospedeiro, Anápolis, GO, Brasil.
概括
低度的聚乙烯比古安化 (PHMB) 导致Biomphalaria glabrata牛的行为变化和能量代谢改变. 这表明PHMBMB.
科学领域:
- 寄生虫学的寄生虫学
- 环境毒理学环境毒理学
- 生物化学 生物化学
背景情况:
- Biomphalaria glabrata 牛传播 Schistosoma mansoni,这种寄生虫会引起.
- 控制杆菌病需要管理牛种群,以中断寄生虫传播.
- 之前的研究表明,聚乙烯比古安化 (PHMB) 导致牛死亡率在1.6毫克L-1.
研究的目的:
- 为了评估PHMB较低度 (0.4,0.6,0.8毫克L-1) 对B. glabrata的影响.
- 评估PHMB对牛行为和生物化学生物标志物的影响.
- 探索PHMB作为载体控制剂的潜力.
主要方法:
- 牛在96小时内暴露在0.4,0.6和0.8毫克L-1的PHMB中.
- 每24小时记录一次行为变化 (昏迷,粘液分泌,外封闭,缺乏运动).
- 血淋巴分析包括葡萄糖,蛋白质,尿素,尿酸,肌素,AST,ALT和代谢途径中间体.
主要成果:
- 显著的行为变化,包括头足群体的暴露和缺乏运动,发生在72%-95%的牛中.
- 暴露于PHMB导致脂肪酸和蛋白质作为替代能源基质的利用.
- 生物化学分析显示了关键代谢指标的变化.
结论:
- 在低于致命的度下,PHMB会诱导B. glabrata的显著行为和代谢变化.
- 能量代谢途径是开发新牛控制策略的有希望的目标.
- 对PHMB对牛能量代谢的影响进行进一步的研究是有必要的,以控制杆菌病.
相关概念视频
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...